Instituto do Cancer do Estado de São Paulo   Report issue

Academic/Hospital Phase 2 Phase 3 Phase 4
Founded: Sao Paulo Brazil (2008)

Organization Overview

First Clinical Trial
2010
NCT02508857
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Fauze Maluf Filho | ICESP - HCFMUSP | Instituto do Cancer do Estado de Sao Paulo | Instituto do Cancer do Estado de São Paulo | Instituto do Câncer do Estado de São Paulo | Instituto do Câncer do Estado de São Paulo | Tiago Biachi

Active Ingredients

Drugs in Phase 4 Trials (7)

aprepitant (Emend) (3 trials)

ketorolac (acuvail) (1 trial)

magnesium oxide (1 trial)

prednisolone (hydeltra) (1 trial)

sodium chloride (1 trial)

triamcinolone (kenalog) (1 trial)

urea (1 trial)

Drugs in Phase 3 Trials (12)

capecitabine (xeloda) (2 trials)

carvedilol (coreg) (1 trial)

droperidol (innovar) (1 trial)

fluorouracil (efudex) (5 trials)

leucovorin (3 trials)

norepinephrine (levophed) (1 trial)

olanzapine (zyprexa) (1 trial)

oxaliplatin (eloxatin) (4 trials)

red blood cells (1 trial)

tanezumab (1 trial)

tranexamic acid (cyklokapron) (1 trial)

vasopressin (vasostrict) (1 trial)

Drugs in Phase 2 Trials (29)

abiraterone (zytiga) (1 trial)

apalutamide (erleada) (1 trial)

bortezomib (velcade) (1 trial)

cisplatin (platinol) (1 trial)

cyclophosphamide (cytoxan) (1 trial)

dexamethasone (1 trial)

docetaxel (taxotere) (1 trial)

doxorubicin (Doxil) (1 trial)

durvalumab (imfinzi) (1 trial)

enzalutamide (xtandi) (1 trial)

ethanolamine (ethamolin) (1 trial)

ferric saccharose (1 trial)

Filgrastim (neupogen) (1 trial)

folfirinox (1 trial)

gemcitabine (gemzar) (1 trial)

goserelin (zoladex) (1 trial)

hu3s193 (1 trial)

irinotecan (Camptosar) (2 trials)

ivermectin (stromectol) (1 trial)

losartan (cozaar) (1 trial)

mitomycin (mutamycin) (2 trials)

nivolumab (opdivo) (1 trial)

ondansetron (zofran) (1 trial)

paclitaxel (taxol) (4 trials)

prednisone (meticorten) (1 trial)

regorafenib (stivarga) (1 trial)

sitagliptin (januvia) (3 trials)

sunitinib (sutent) (1 trial)

valproic acid (depakene) (1 trial)

Drugs in Other Trials (6)

carboplatin (paraplatin) (1 trial)

fentanyl (Innovar) (1 trial)

formaldehyde (1 trial)

hydrocortisone (solu-cortef) (1 trial)

mitoquinone (1 trial)

trastuzumab (herceptin) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Adenocarcinoma (Phase 3)

Breast Neoplasms (Phase 2)

Cancer Pain (Phase 3)

Carcinoma (Phase 2)

Carcinoma, Renal Cell (Phase 2)

Carcinoma, Squamous Cell (Phase 2)

Cardiotoxicity (Phase 3)

Colorectal Neoplasms (Phase 2)

Constriction, Pathologic (Phase 4)

Coronavirus Infections (Phase 2)

Esophageal Squamous Cell Carcinoma (Phase 2)

Esophageal Stenosis (Phase 4)

Head and Neck Neoplasms (Phase 2)

Heart Failure (Phase 3)

Infections (Phase 2)

Mouth Neoplasms (Phase 2)

Musculoskeletal Pain (Phase 3)

Nausea (Phase 4)

Neoplasm Metastasis (Phase 3)

Neoplasms (Phase 2)

Neuroendocrine Tumors (Phase 2)

Oropharyngeal Neoplasms (Phase 2)

Pain, Postoperative (Phase 4)

Pancreatic Neoplasms (Phase 2)

Postoperative Nausea and Vomiting (Phase 4)

Prostatic Neoplasms (Phase 2)

Severe Acute Respiratory Syndrome (Phase 2)

Shock (Phase 3)

Shock, Septic (Phase 3)

Squamous Cell Carcinoma of Head and Neck (Phase 2)

Stomach Neoplasms (Phase 2)

Vomiting (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 40
  • # of Trial APIs: 54